Low Leverage / Strong Balance SheetSustained low leverage and stable-to-growing equity provide financial resilience, lowering bankruptcy and refinancing risk. This structural strength preserves capacity to fund R&D, M&A, or dividend policy and cushions the business through cyclical pharma demand swings.
Consistent Operating Cash GenerationRepeated positive operating cash flow demonstrates underlying cash-generative operations independent of accounting profits. Over months, this supports sustainable capex, working-capital management, and dividends without heavy refinancing, improving long-term operational flexibility.
Stable Gross Margin ProfileA steady low-20% gross margin indicates durable product-level economics and consistent cost control, which helps preserve core profitability. This margin stability gives management predictable input for pricing and cost planning despite low overall net margins.